Market Cap 8.15B
Revenue (ttm) 616.29M
Net Income (ttm) 447.18M
EPS (ttm) N/A
PE Ratio 17.70
Forward PE 34.11
Profit Margin 72.56%
Debt to Equity Ratio 1.28
Volume 7,172,500
Avg Vol 2,235,660
Day's Range N/A - N/A
Shares Out 153.08M
Stochastic %K 94%
Beta 1.68
Analysts Strong Sell
Price Target $48.00

Company Profile

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The com...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 554 4484
Fax: 212 554 4531
Address:
3020 Carrington Mill Blvd., Suite 475, Morrisville, United States
moreyoucando
moreyoucando Jun. 20 at 3:27 AM
$TGTX from article on azer-cell trial - one patient On day 90, she also went through her initial baseline tests and had a lumbar puncture.“I improved on all of the tests,” she says. “My baseline 25-foot timed walk test was 17. After day 90, it was 7.2. A normal person is 3 or less.”In the months since then, Janisch-Hanzlik has noticed other improvements as well.“I wear glasses for double vision, and one day I realized it was gone. My urinating hesitancy slowly went away. My gait is so much better that I don’t use a cane in the house. And I went from taking at least a three-hour nap a day to not taking a nap at all,” she says.“When I go into my doctor’s office, they’re so impressed — they can really notice quite an improvement just by talking to me, watching me walk in, without doing any tests. My physical therapist is so amazed by the improvements.”As part of the clinical trial,“We have no idea what will happen in two years, but I feel like I’m improving every day,” she says.
0 · Reply
GordoHLYK13
GordoHLYK13 Jun. 20 at 1:26 AM
$IGC $IGC 🚀 Ascendiant’s $5.50 price target on a $0.28 stock reflects what could happen if IGC delivers on its pipeline. ✅ Huge Alzheimer’s agitation market with limited approved treatments. ✅ Clinical validation from the prestigious Icahn School of Medicine at Mount Sinai joining the CALMA study. ✅ Multiple 2026 catalysts including IGC-AD1, AI-driven trial optimization, and TGR-63. ✅ Strong global patent protection creating a potential competitive moat. Ascendiant sees a micro-cap with a tiny valuation sitting on a potentially massive commercial opportunity. If Phase 2 data hits, this may not be a simple move higher—it could be a complete re-rating of the company. 🚀📈 #IGC #Alzheimers #Biotech #AI #HealthcareStocks The bull case: A company valued around $27M today could see a major re-rating if Phase 2 data is positive and even a small share of this multi-billion-dollar market is captured. 🚀📈 #IGC #Alzheimers #Biotech $MRNA $LLY $NVAX $TGTX
0 · Reply
ngyojiw
ngyojiw Jun. 20 at 12:37 AM
$TGTX I will rather get Biohaven for 10B!!
0 · Reply
ngyojiw
ngyojiw Jun. 20 at 12:33 AM
$TGTX another typical shit goes for dozen Billions that in most likely will fail Phase 3 or at most do meagre sales many years after. thats why this deserves at least 30B.
0 · Reply
Gshc22
Gshc22 Jun. 19 at 9:25 PM
$TGTX Please guys, stop it ! Dont compare APGE or any others BO like IMMU to give Tgtx a price based on others BO. It's not the way it works.
1 · Reply
Bio_investor_
Bio_investor_ Jun. 19 at 9:19 PM
$TGTX No wonder why Mike deserves to have 16-20B. Apogee Therapeutics (NASDAQ: APGE) currently has $0 in revenue. Because they are a clinical-stage biotechnology company focused on developing biologics for inflammatory diseases (like their lead drug candidate, zumilokibart, for atopic dermatitis), they do not yet have an approved product on the market to generate commercial sales. This is completely standard for biotech companies at this stage of development. While they don't have revenue, their financial profile is defined by a heavy focus on clinical pipeline development and strategic funding: Net Loss: They reported a net loss of roughly $74.1 million for Q1 2026, which is driven by their research and development (R&D) and general administrative expenses as they scale their clinical trials.
0 · Reply
JuliusW
JuliusW Jun. 19 at 8:55 PM
$TGTX Congratulations to the long holders here on Briumvi and what's happening. I owned the stock a few years ago, before I started posting. I remember some of you, and your dogs. Much success to come!
0 · Reply
Wolves1
Wolves1 Jun. 19 at 8:01 PM
$TGTX @Pennzwoods 🤔
0 · Reply
WirthM13
WirthM13 Jun. 19 at 7:10 PM
$TGTX David Audet on X posted this National MS Society article on the first test patient for Azer-cel. Great results and her treatment story. https://www.nationalmssociety.org/news-and-magazine/momentum-magazine/research-and-science/car-t-cell-therapy
0 · Reply
Jcljack26
Jcljack26 Jun. 19 at 6:55 PM
$TGTX $16B offer would be on the lower side for $TGTX after the $APGE deal
1 · Reply
Latest News on TGTX
TG Therapeutics Transcript: AGM 2026

Jun 11, 2026, 9:30 AM EDT - 8 days ago

TG Therapeutics Transcript: AGM 2026


TG Therapeutics rises 10.6%

2026-06-03T16:07:12.000Z - 16 days ago

TG Therapeutics rises 10.6%


TG Therapeutics announces results from Briumvi trial

2026-06-03T12:06:50.000Z - 16 days ago

TG Therapeutics announces results from Briumvi trial


TG Therapeutics reports ENHANCE trial meets primary endpoint

2026-05-27T12:20:45.000Z - 23 days ago

TG Therapeutics reports ENHANCE trial meets primary endpoint


TG Therapeutics reports Q1 EPS 12c, consensus 28c

2026-05-07T07:02:48.000Z - 6 weeks ago

TG Therapeutics reports Q1 EPS 12c, consensus 28c


TG Therapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 8:30 AM EDT - 6 weeks ago

TG Therapeutics Earnings Call Transcript: Q1 2026


TG Therapeutics Earnings release: Q1 2026

May 6, 2026, 8:30 AM EDT - 6 weeks ago

TG Therapeutics Earnings release: Q1 2026


TG Therapeutics Quarterly report: Q1 2026

May 6, 2026, 8:30 AM EDT - 6 weeks ago

TG Therapeutics Quarterly report: Q1 2026


TG Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 7 weeks ago

TG Therapeutics Proxy statement: Proxy filing


TG Therapeutics completes enrollment in Briumvi trial

2026-04-15T11:48:15.000Z - 2 months ago

TG Therapeutics completes enrollment in Briumvi trial


TG Therapeutics board expands share repurchase program to $300M

2026-03-19T12:01:19.000Z - 3 months ago

TG Therapeutics board expands share repurchase program to $300M


TG Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

TG Therapeutics Earnings Call Transcript: Q4 2025


TG Therapeutics Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

TG Therapeutics Annual report: Q4 2025


TG Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

TG Therapeutics Earnings release: Q4 2025


TG Therapeutics reports Q4 EPS 14c, consensus 33c

2026-02-26T12:08:07.000Z - 4 months ago

TG Therapeutics reports Q4 EPS 14c, consensus 33c


TG Therapeutics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:30 AM EST - 8 months ago

TG Therapeutics Earnings Call Transcript: Q3 2025


TG Therapeutics Quarterly report: Q3 2025

Nov 3, 2025, 8:30 AM EST - 8 months ago

TG Therapeutics Quarterly report: Q3 2025


TG Therapeutics Earnings release: Q3 2025

Nov 3, 2025, 8:30 AM EST - 8 months ago

TG Therapeutics Earnings release: Q3 2025


TG Therapeutics Earnings Call Transcript: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 11 months ago

TG Therapeutics Earnings Call Transcript: Q2 2025


TG Therapeutics Quarterly report: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 11 months ago

TG Therapeutics Quarterly report: Q2 2025


TG Therapeutics Earnings release: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 11 months ago

TG Therapeutics Earnings release: Q2 2025


TG Therapeutics Earnings Call Transcript: Q1 2025

May 5, 2025, 8:30 AM EDT - 1 year ago

TG Therapeutics Earnings Call Transcript: Q1 2025


TG Therapeutics Quarterly report: Q1 2025

May 5, 2025, 8:30 AM EDT - 1 year ago

TG Therapeutics Quarterly report: Q1 2025


TG Therapeutics Earnings release: Q1 2025

May 5, 2025, 8:30 AM EDT - 1 year ago

TG Therapeutics Earnings release: Q1 2025


TG Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

TG Therapeutics Proxy statement: Proxy Filing


TG Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

TG Therapeutics Proxy statement: Proxy Filing


TG Therapeutics Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

TG Therapeutics Proxy statement: Proxy Filing


TG Therapeutics Earnings Call Transcript: Q4 2024

Mar 3, 2025, 8:30 AM EST - 1 year ago

TG Therapeutics Earnings Call Transcript: Q4 2024


TG Therapeutics Annual report: Q4 2024

Mar 3, 2025, 8:30 AM EST - 1 year ago

TG Therapeutics Annual report: Q4 2024


TG Therapeutics Earnings release: Q4 2024

Mar 3, 2025, 8:30 AM EST - 1 year ago

TG Therapeutics Earnings release: Q4 2024


TG Therapeutics Slides: FY 2025

Jan 13, 2025, 7:30 PM EST - 1 year ago

TG Therapeutics Slides: FY 2025


TG Therapeutics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 8:30 AM EST - 1 year ago

TG Therapeutics Earnings Call Transcript: Q3 2024


TG Therapeutics Quarterly report: Q3 2024

Nov 4, 2024, 8:30 AM EST - 1 year ago

TG Therapeutics Quarterly report: Q3 2024


TG Therapeutics Earnings release: Q3 2024

Nov 4, 2024, 8:30 AM EST - 1 year ago

TG Therapeutics Earnings release: Q3 2024


moreyoucando
moreyoucando Jun. 20 at 3:27 AM
$TGTX from article on azer-cell trial - one patient On day 90, she also went through her initial baseline tests and had a lumbar puncture.“I improved on all of the tests,” she says. “My baseline 25-foot timed walk test was 17. After day 90, it was 7.2. A normal person is 3 or less.”In the months since then, Janisch-Hanzlik has noticed other improvements as well.“I wear glasses for double vision, and one day I realized it was gone. My urinating hesitancy slowly went away. My gait is so much better that I don’t use a cane in the house. And I went from taking at least a three-hour nap a day to not taking a nap at all,” she says.“When I go into my doctor’s office, they’re so impressed — they can really notice quite an improvement just by talking to me, watching me walk in, without doing any tests. My physical therapist is so amazed by the improvements.”As part of the clinical trial,“We have no idea what will happen in two years, but I feel like I’m improving every day,” she says.
0 · Reply
GordoHLYK13
GordoHLYK13 Jun. 20 at 1:26 AM
$IGC $IGC 🚀 Ascendiant’s $5.50 price target on a $0.28 stock reflects what could happen if IGC delivers on its pipeline. ✅ Huge Alzheimer’s agitation market with limited approved treatments. ✅ Clinical validation from the prestigious Icahn School of Medicine at Mount Sinai joining the CALMA study. ✅ Multiple 2026 catalysts including IGC-AD1, AI-driven trial optimization, and TGR-63. ✅ Strong global patent protection creating a potential competitive moat. Ascendiant sees a micro-cap with a tiny valuation sitting on a potentially massive commercial opportunity. If Phase 2 data hits, this may not be a simple move higher—it could be a complete re-rating of the company. 🚀📈 #IGC #Alzheimers #Biotech #AI #HealthcareStocks The bull case: A company valued around $27M today could see a major re-rating if Phase 2 data is positive and even a small share of this multi-billion-dollar market is captured. 🚀📈 #IGC #Alzheimers #Biotech $MRNA $LLY $NVAX $TGTX
0 · Reply
ngyojiw
ngyojiw Jun. 20 at 12:37 AM
$TGTX I will rather get Biohaven for 10B!!
0 · Reply
ngyojiw
ngyojiw Jun. 20 at 12:33 AM
$TGTX another typical shit goes for dozen Billions that in most likely will fail Phase 3 or at most do meagre sales many years after. thats why this deserves at least 30B.
0 · Reply
Gshc22
Gshc22 Jun. 19 at 9:25 PM
$TGTX Please guys, stop it ! Dont compare APGE or any others BO like IMMU to give Tgtx a price based on others BO. It's not the way it works.
1 · Reply
Bio_investor_
Bio_investor_ Jun. 19 at 9:19 PM
$TGTX No wonder why Mike deserves to have 16-20B. Apogee Therapeutics (NASDAQ: APGE) currently has $0 in revenue. Because they are a clinical-stage biotechnology company focused on developing biologics for inflammatory diseases (like their lead drug candidate, zumilokibart, for atopic dermatitis), they do not yet have an approved product on the market to generate commercial sales. This is completely standard for biotech companies at this stage of development. While they don't have revenue, their financial profile is defined by a heavy focus on clinical pipeline development and strategic funding: Net Loss: They reported a net loss of roughly $74.1 million for Q1 2026, which is driven by their research and development (R&D) and general administrative expenses as they scale their clinical trials.
0 · Reply
JuliusW
JuliusW Jun. 19 at 8:55 PM
$TGTX Congratulations to the long holders here on Briumvi and what's happening. I owned the stock a few years ago, before I started posting. I remember some of you, and your dogs. Much success to come!
0 · Reply
Wolves1
Wolves1 Jun. 19 at 8:01 PM
$TGTX @Pennzwoods 🤔
0 · Reply
WirthM13
WirthM13 Jun. 19 at 7:10 PM
$TGTX David Audet on X posted this National MS Society article on the first test patient for Azer-cel. Great results and her treatment story. https://www.nationalmssociety.org/news-and-magazine/momentum-magazine/research-and-science/car-t-cell-therapy
0 · Reply
Jcljack26
Jcljack26 Jun. 19 at 6:55 PM
$TGTX $16B offer would be on the lower side for $TGTX after the $APGE deal
1 · Reply
WirthM13
WirthM13 Jun. 19 at 6:30 PM
$TGTX Saw this DTC (direct to consumer) link on NYTimes Well newsletter for MS info. Turns out it's O and Z blurb. Somebody getting nervous? https://www.nytimes.com/paidpost/genentech/less-time-in-treatment.html?smid=url-share.
1 · Reply
Wolves1
Wolves1 Jun. 19 at 5:52 PM
$TGTX Cody is watching from above ......
0 · Reply
Wolves1
Wolves1 Jun. 19 at 5:47 PM
$TGTX sniff, sniff .....
0 · Reply
moreyoucando
moreyoucando Jun. 19 at 3:31 PM
$TGTX Biotech acquisitions are getting expensive. Apogee has not even started a Phase 3.... https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-nears-11-billion-deal-apogee-therapeutics-ft-reports-2026-06-19/
0 · Reply
jea1968
jea1968 Jun. 19 at 3:19 PM
$TGTX this is up 8% today on the German stock market. Ticker is NKB2…
4 · Reply
CedarPark
CedarPark Jun. 19 at 3:08 PM
$TGTX Been a good run, should keep going. IBD has what looks like a very positive article on us. RSI short-term overbought, but I am feeling the POWER behind this - we will keep rising anyways. Buying any dip. > https://www.investors.com/research/the-new-america/tg-therapeutics-stock-briumvi-myasthetia-gravis-subcutaneous/
0 · Reply
CT_Biker
CT_Biker Jun. 19 at 3:03 PM
$TGTX Halt?
0 · Reply
ngyojiw
ngyojiw Jun. 19 at 4:45 AM
$TGTX $50? it doesnt even catch a glimpse of full Briumvi Potential - let alone subQ potential (So double that). + Azer - cel & Briumvi MG. its a pipelines within a pipeline. sure i left something too the last time we move >10$ we got hit close to -20$ like March 2025 onwards and another one early this year. so have to be calm, alert and dont take it for granted. really those downward moves should never happen. This drug is soo much better than bbio or insm drugs yet they still doubles than tg value, wheres the fairness!! wheres the anger!!. march and rise on tg warriors!
1 · Reply
Son_of_Shango
Son_of_Shango Jun. 19 at 4:02 AM
$TGTX The Facebook Briumvi group hit 3.4k members.
1 · Reply
calbucs
calbucs Jun. 19 at 12:31 AM
$TGTX Short Interest went up , not by much but still up , stubborn shorts not going away , if we do get a short squeeze this flies to $80 plus , the pain will continue to grow .
3 · Reply
ngyojiw
ngyojiw Jun. 19 at 12:22 AM
$TGTX This should do Double or Triple the average of AXSM BBIO and INSM did since 2025! Due to super duper blockbuster that those companies dont have. So dont be easily satisfied. Some companies are sold for 20B and doing measly revenues. Then how much should TG go? the last 5 years TG has been undervalued. It only makes sense the next 5 years (starting 2026) or so, it will be overvalued.
0 · Reply
BearCrusher
BearCrusher Jun. 18 at 11:49 PM
$TGTX anyone have any recommendations for the next tgtx in bio?